Related references
Note: Only part of the references are listed.Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Francois Vaillant et al.
CANCER CELL (2013)
BCL-2: A New Therapeutic Target in Estrogen Receptor-Positive Breast Cancer?
Lesley-Ann Martin et al.
CANCER CELL (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas
Sabina Berezowska et al.
PLOS ONE (2013)
The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer
Z. M. A. Mohammed et al.
BRITISH JOURNAL OF CANCER (2012)
Leukocyte composition of human breast cancer
Brian Ruffell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The interaction between ER and NFκB in resistance to endocrine therapy
Leen Sas et al.
BREAST CANCER RESEARCH (2012)
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer
E. A. Reijm et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease
S. E. Clark et al.
BRITISH JOURNAL OF CANCER (2011)
Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions
Flora Zagouri et al.
BMC CANCER (2010)
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
S-J Dawson et al.
BRITISH JOURNAL OF CANCER (2010)
The BCL-2 Family Reunion
Jerry E. Chipuk et al.
MOLECULAR CELL (2010)
Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer-Specific Immune Responses and Their Correlation to Prognosis
Christoph Domschke et al.
CANCER RESEARCH (2009)
Inflammation, Microenvironment, and the Immune System in Cancer Progression
Andrew Keibel et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
RelB NF-κB Represses Estrogen Receptor α Expression via Induction of the Zinc Finger Protein Blimp1
Xiaobo Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
The glucocorticoid responses are shaped by molecular chaperones
Wona Grad et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2007)
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo
Sven A. Lang et al.
MOLECULAR CANCER THERAPEUTICS (2007)
International Union of Pharmacology.: LXIV.: Estrogen receptors
Karin Dahlman-Wright et al.
PHARMACOLOGICAL REVIEWS (2006)
Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation
Fumitaka Koga et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Human disease resulting from gene mutations that interfere with appropriate nuclear factor-κB activation
JS Orange et al.
IMMUNOLOGICAL REVIEWS (2005)
Progesterone receptors: Various forms and functions in reproductive tissues
S Gadkar-Sable et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2005)
Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
P Workman
CANCER LETTERS (2004)
Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness
BK Eustace et al.
NATURE CELL BIOLOGY (2004)
Bcl-2 family member Bfl-1/A1 sequesters truncated bid to inhibit its collaboration with pro-apoptotic Bak or Bax
AB Werner et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance
KC Kregel
JOURNAL OF APPLIED PHYSIOLOGY (2002)
Bcl-2 family proteins as targets for anticancer drug design
ZW Huang
ONCOGENE (2000)
Share Paper
